Revised psychopharmacological algorithms for the treatment of mood disorders in Japan

References

• Murray CLJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436–42
   PubMed Web of Science ®Google Scholar
• Higuchi T, Fujiwara Y, Iida M, et al. Algorithm for the treatment of mood disorders in Japan. Int J Psychiatr Clin Pract 1999; 3: 277–85
   PubMedGoogle Scholar
• Sato M, Nakane N, Hayashida M T, et al. Algorithms for the treatment of schizophrenia in Japan. Int J Psychiatr Clin Pract 1999; 3: 271–6
   PubMedGoogle Scholar
• Shioe K. Pharmacotherapy of depression. Clinical Psychiatry 2006;46:1335–45 ( in Japanese).
   Google Scholar
• Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disrord 2000; 58: 19–36
   PubMed Web of Science ®Google Scholar
• Montgomery SA. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int Clin Psychopharmacol 2001; 16: 169–78
   PubMed Web of Science ®Google Scholar
• Aoba A, Tanaka Y, Kageyama S, , et al. A post-marketing clinical study of paroxetine hydrochloride hydrate in patients with depression or depressive episodes: A double-blind, imipramine hydrochloride-controlled, comparative study. Jpn J Clin Psychopharmacol 2004;7:831–53 ( in Japanese).
   Google Scholar
• Asakura M, Tajima O. A randomized, double-bind study of fluvoxamine maleate inpatients with depression or depressive state: A comparison in anticholinergic effects and cardiovascular adverse reactions between fluvoxamine maleate and imipramine hydrochloride. Jpn Pharmacol Ter 2005; 33: 773–87
   Google Scholar
• Otsubo T, Akimoto Y, Yamada H, et al. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression. Pharmacopsychiatry 2005; 38: 30–5
   PubMed Web of Science ®Google Scholar
• Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997; 12: 99–108
   PubMed Web of Science ®Google Scholar
• Furukawa TA, Streiner DL, Young LT. Antidepressant and benzodiazepine for major depression. Cochrane Database Syst Rev 2002; 1: CD001026
   Google Scholar
• Kennedy S, McIntyre R, Fallu A, Lam R. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 2002; 27: 269–80
   PubMed Web of Science ®Google Scholar
• Baker CB, Tweedie R, Duval S, Woods SW. Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis. Depress Anxiety 2003; 17: 1–9
   PubMed Web of Science ®Google Scholar
• Bauer M, Forsthoff A, Baethge C, et al. Lithium augmentation therapy in refractory depression – Update 2002. Eur Arch Psychiatry Clin Neurosci 2003; 253: 132–9
   PubMed Web of Science ®Google Scholar
• Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996; 53: 842–8
   PubMed Web of Science ®Google Scholar
• Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131–4
   PubMed Web of Science ®Google Scholar
• Inoue T, Tsuchiya K, Miura J, et al. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry 1996; 40: 151–3
   PubMed Web of Science ®Google Scholar
• Segrave R, Nathan PJ. Pindolol augmentation of selective serotonin reuptake inhibitors: Accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Hum Psychopharmacol 2005; 20: 163–74
   PubMed Web of Science ®Google Scholar
• Landen M, Bjorling G, Agren H, Fahlen T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment–refractory depression. J Clin Psychiatry 1998; 59: 664–8
   PubMed Web of Science ®Google Scholar
• Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001; 62: 448–52
   PubMed Web of Science ®Google Scholar
• The UK ECT review group. Efficacy and safety of electroconvulsive therapy in depressive disorder: a systematic review and meta-analysis. Lancet 2003;361:799–808.
   PubMed Web of Science ®Google Scholar
• Tzanakaki M, Guazzelli M, Nimatoudis I, Zissis NP, Smeraldi E, Rizzo F. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol 2000; 15: 29–34
   PubMed Web of Science ®Google Scholar
• Anton RF, Jr, Burch EA, Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry 1990; 147: 1203–8
   PubMed Web of Science ®Google Scholar
• Anton RF, Jr, Burch EA, Jr. Response of psychotic depression subtypes to pharmacotherapy. J Affect Disord 1993; 28: 125–31
   PubMed Web of Science ®Google Scholar
• Zanardi R, Franchini L, Serretti A, Perez J, Smeraldi E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry 2000; 61: 26–9
   PubMed Web of Science ®Google Scholar
• Spiker DG, Weiss JC, Delay RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985; 142: 430–6
   PubMed Web of Science ®Google Scholar
• Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH. A meta-analysis of electroconvulsive therapy efficacy in depression. J ECT 2003; 19: 139–47
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004; 24: 365–73
   PubMed Web of Science ®Google Scholar
• Emilien G, Maloteaux JM, Seghers A, Charles G. Lithium compared to valproic acid and carbamazepine in the treatment of mania. A statistical meta-analysis. Eur Neuropsychopharmacol 1996; 6: 245–52
   PubMed Web of Science ®Google Scholar
• Poolsup N, Li Wan Po A, de Oliveira IR. Systematic overview of lithium treatment in acute mania. J Clin Pharm Ther 2000; 25: 139–56
   PubMed Web of Science ®Google Scholar
• Macritchie K, Geddes JR, Scott J, Haslam D, de Lima M, Goodwin G. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev 2003; 1: CD004052
   PubMedGoogle Scholar
• Kudo Y, Ichimaru S, Kawakita Y, , et al. Comparison of therapeutic effect on mania of sultopride hydrochloride with haloperidol using double-blind technique. Clin Eval 1987;15:15–36 ( in Japanese).
   Google Scholar
• Harada T, Otsuki S, Yamashita I, , et al. Double-blind comparative study on antimanic effects of zotepine and lithium carbonate. Jpn J Clin Psychiatry 1994;23:1249–62 ( in Japanese).
   Google Scholar
• Rendell JM, Gijsman HJ, Keck P, Goodwin GM, Geddes JR. Olanzapine alone or in combination for acute mania. Cochrane Database Syst Rev 2003; 3: CD004040
   Google Scholar
• Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 2005; 21: 923–34
   PubMed Web of Science ®Google Scholar
• Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998; 21: 176–80
   PubMed Web of Science ®Google Scholar
• Yatham LN, Grossman F, Augustynus I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania: International, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182: 141–7
   PubMed Web of Science ®Google Scholar
• Hirschfeld RMA, Keck PE, Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004; 161: 1057–65
   PubMed Web of Science ®Google Scholar
• Small JG, Klapper MH, Marhenke JD, Milstein V, Woodham GC, Kellams JJ. Lithium combined with carbamazepine or haloperidol in the treatment of mania. Psychopharmacol Bull 1995; 31: 265–72
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Sackeim HA, Schnur DB. Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. Am J Psychiatry 1994; 151: 169–76
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Evans DL, Guylai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158: 906–12
   PubMed Web of Science ®Google Scholar
• Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000; 157: 124–6
   PubMed Web of Science ®Google Scholar
• Vieta E, Martinez-Aran A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002; 63: 508–12
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990; 147: 431–4
   PubMed Web of Science ®Google Scholar
• Joyce PR. Carbamazepine in rapid cycling bipolar affective disorder. Int Clin Psychopharmacol 1988; 3: 123–9
   PubMed Web of Science ®Google Scholar
• Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorders. II. Treatment of refractory rapid cycling with high-dose levothyroxine. Arch Gen Psychiatry 1990; 47: 435–40
   PubMed Web of Science ®Google Scholar
• Morishita S, Aoki S, Watanabe S. Clonazepam as a therapeutic adjunct to improve the management of psychiatric disorders. Psychiatry Clin Neurosci 1998; 52: 75–8
   PubMed Web of Science ®Google Scholar
• Sanger TM, Tohen M, Vieta E, et al. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord 2003; 73: 155–61
   PubMed Web of Science ®Google Scholar
• Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988; 145: 179–84
   PubMed Web of Science ®Google Scholar
• Standish-Barry HM, Bouras N, Bridges PK, Watson JP. A randomized double blind group comparative study of sulpiride and amitriptyline in affective disorder. Psychopharmacology 1983; 81: 258–60
   PubMed Web of Science ®Google Scholar